Addex Therapeutics Ltd (ADXN)

USD 7.62

(-4.51%)

Market Cap (In USD)

12.34 Million

Revenue (In USD)

1.61 Million

Net Income (In USD)

-10.55 Million

Avg. Volume

286.73 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.39-27.9
PE
-
EPS
-
Beta Value
1.874
ISIN
US00654J2069
CUSIP
00654J107
CIK
1574232
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Timothy Mark Dyer
Employee Count
-
Website
https://www.addextherapeutics.com
Ipo Date
2020-02-12
Details
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.